Exelixis Q4 Adj EPS $0.33 Beats $0.22 Estimate, Sales $479.65M Miss $484.88M Estimate
Portfolio Pulse from saritha@benzinga.com
Exelixis (NASDAQ:EXEL) reported Q4 adjusted EPS of $0.33, surpassing the $0.22 estimate, marking a 1200% increase from last year's losses. However, their sales of $479.65M fell short of the $484.88M estimate, despite being a 13.15% increase from the previous year.
February 06, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Exelixis reported a significant beat on adjusted EPS for Q4 but slightly missed sales estimates. The EPS beat and year-over-year growth are positive, but the sales miss could temper enthusiasm.
The substantial beat on EPS suggests strong profitability and operational efficiency, which is typically positive for stock prices. However, the slight miss on sales estimates indicates that revenue growth, while still positive, didn't meet expectations. This mixed result could lead to neutral short-term stock price movement as investors weigh the positives against the slight negative.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100